News & Updates
Filter by Specialty:
Double trouble: Alcohol-related liver diseases take a turn for the worse during COVID-19
Higher intake of alcohol and reduced care during the COVID-19 pandemic have triggered a spike in alcohol-related liver diseases, leading to some serious consequences, according to new research.
Double trouble: Alcohol-related liver diseases take a turn for the worse during COVID-19
15 Nov 2021Asthma, high BMI, older age up risk of small airway dysfunction
Small airway disfunction can lead to increased airway resistance and visible computed tomography (CT) changes, according to a study. Furthermore, this disease is more common among individuals with advanced age, high body mass index (BMI), childhood cough, and asthma.
Asthma, high BMI, older age up risk of small airway dysfunction
14 Nov 2021Dietary acrylamide compromises physical performance in knee OA
In people with knee osteoarthritis (OA) or are at high risk of such condition, dietary acrylamide seems to worsen physical performance and may potentially increase the risk of sarcopoenia, a recent study has found.
Dietary acrylamide compromises physical performance in knee OA
14 Nov 2021Statin confers cardioprotection, survival benefit for middle-aged, older diabetics
Statin reduces the risk of cardiovascular disease and mortality in type 2 diabetes, and this beneficial effect is evident among middle-aged and, to a lesser extent, older patients but not among young patients, a study has found.
Statin confers cardioprotection, survival benefit for middle-aged, older diabetics
14 Nov 2021Medicine uptitration amps up RDN benefit for drug-resistant hypertension
In patients with multidrug-resistant hypertension (HTN), the blood pressure (BP)-lowering benefit of renal denervation (RDN) achieved at 2 months was amplified when a stepped-care medication escalation protocol was added between 2 and 6 months, updates from the RADIANCE-HTN TRIO trial have shown.
Medicine uptitration amps up RDN benefit for drug-resistant hypertension
14 Nov 2021Chemoimmunotherapeutic agents boost lymphocytic leukaemia survival
The introduction and use of chemoimmunotherapeutic agents such as rituximab, ofatumumab, and obinutuzumab has led to population-level improvements in survival from chronic lymphocytic leukaemia (CLL), a recent study has found.